Centre Medical Announces $Tens of Millions Series A Funding to Expand Cardiovascular Specialty Clinics Across Asia

VCBeat has learned that,Hong Kong-headquartered cardiovascular specialty healthcare chain Centre Medical has recently completed a tens-of-millions-of-US-dollars Series A financing round. The round was led by Qingshi Capital, with participation from Hong Kong Asia Healthcare Group. Haoyue Capital served as the exclusive financial advisor for this financing. The funds will support Centre Medical in continuing to implement its internationalization strategy and further expanding its presence in Japan and Southeast Asia.

Centre Medical XianDe Medical, founded in 2014 by Professor Lin Yixian, a leading cardiovascular specialist in Hong Kong, brings together top-tier international medical and management talents from China, Japan, and across Asia. The company is committed to building the most professional cardiovascular specialty clinic chain brand in Asia. Currently, it operates three clinics in Hong Kong, providing one-stop cardiovascular specialty medical services covering pre-operative, intra-operative, and rehabilitation care.

Xiande Medical will continue to implement its international expansion strategy, initially perfecting its global footprint within the next year in Japan, Indonesia, and other Southeast Asian regions by collaborating with local top-tier physician teams. Meanwhile, leveraging sustained and deepening cooperation with Hong Kong Asia Healthcare Group and strategic partners across Southeast Asian countries, Xiande Medical will utilize its reserve of Asia’s leading physicians and premium surgical facilities to jointly develop undervalued healthcare service markets with local strategic investment institutions. By introducing the highest-quality physician resources, innovative technologies, and service concepts from across Asia to regions in Southeast Asia with relatively scarce medical resources, Xiande Medical aims to ultimately achieve a pan-Asian presence characterized by professional leadership and operational efficiency.

Professor Lin Yixian, Founder and CEO of Xiande MedicalStatement: Since its inception, Xiande Medical has adhered to the core values of science, innovation, and empathy, deeply rooted in the cardiovascular specialty sector, always prioritizing patients’ life and health. We are honored to partner with Qichi Capital in this funding round. I believe that, with the support of all shareholders, Xiande Medical will continue to accelerate its development, forge partnerships with more collaborators across diverse regions in Asia, and rapidly complete its strategic layout throughout the Asian market.

Dr. Li Bin, Founder of Qingchi CapitalStatement: Professor Lin Yixian is a globally recognized top expert in the field of structural heart disease. Qingchi Capital is delighted to participate in and support Professor Lin’s expansion of Xiande Cardiovascular Specialty Clinic Chain, which he founded, into Asian markets beyond Hong Kong. Population aging is a common social challenge faced by countries at different stages of development across Asia. The incidence of cardiovascular diseases and the unmet demand for routine medical care are increasing day by day. We believe that, under Professor Lin’s leadership and with the support and synergy of Hong Kong Asia Healthcare Group, Xiande Cardiovascular Clinic Chain will successfully replicate its clinical expertise and healthcare management experience—already validated through years of practice in the Hong Kong market—and extend them to more countries and regions in Asia, thereby benefiting a broad patient population in these localities.

Guo Yixin, Partner at Haoyue CapitalStatement: Haoyue Capital is honored to have assisted Xiande Medical in completing this financing round. In recent years, as China’s healthcare industry expands globally, outstanding healthcare service brands have gained increasing recognition across more regions. Professor Lin Yixian, Founder of Xiande Medical, has long enjoyed an international reputation in the field of cardiovascular medicine and possesses extensive experience in translating innovative medical technologies from research and development into practical applications, as well as in the operational management of healthcare services. We look forward to Xiande Medical integrating high-quality, reliable healthcare services with cutting-edge international advanced technologies and extending its reach to more countries and regions in Asia.

Headquartered in Hong Kong, China and Shanghai, Lake Bleu Capital is an investment platform focused on the healthcare sector, with assets under management totaling billions of US dollars. Its secondary market USD fund is one of the longest-established and largest healthcare-focused secondary market funds in Asia. Lake Bleu Capital is also active in private equity investments within the Asian healthcare industry, having successfully invested in nearly 60 outstanding healthcare companies. The firm provides diverse value-added services, supporting its portfolio companies in capital operations and business collaborations.